PMID: 8593755Jul 1, 1995Paper

The influence of thioctic acid on metabolism and function of the diabetic heart

Diabetes Research and Clinical Practice
D StrödterK Federlin

Abstract

Streptozotocin-diabetes as a model for insulin-deficient Type 1 diabetes leads to cardiomyopathy, characterized by a 50% reduced glucose uptake (P < 0.001) and increased lactate and pyruvate levels (P < 0.001), i.e. a reduced glucose utilization by the heart. As thioctic acid (TA) has favourable effects on glucose metabolism, the influence of this drug at two different doses (0.1 mg/ml and 0.5 mg/ml, added to the perfusion medium) was investigated in the heart after 2 weeks of diabetes, using the working rat heart model at physiological workload about 45 min. TA at high doses led to a normalization of glucose uptake (P < 0.001) and glucose utilization, and consequently to a normalization of oxygen uptake (P < 0.001), myocardial ATP levels (P < 0.001) as well as cardiac output (P < 0.05). Whereas a low dose of TA resulted in a normalization of lactate and pyruvate production (P < 0.001), neither a normalization of glucose utilization nor of cardiac output was achieved by this low dosage. Additionally, TA improved at both doses utilization of endogenous glycogen in the diabetic heart (P < 0.001), the latter here already delivering 45% of the utilized glucose. TA acts especially by increasing glucose uptake, glycogen breakdown and...Continue Reading

References

Feb 1, 1979·Circulation Research·K Kobayashi, J R Neely
Mar 1, 1979·Circulation Research·D FeuvrayJ R Neely
Oct 1, 1992·Cardiovascular Research·B Rodrigues, J H McNeill
Mar 17, 1986·Life Sciences·A G Tahiliani, J H McNeill
Dec 29, 1970·Biochimica Et Biophysica Acta·N Haugaard, E S Haugaard
Jun 1, 1983·Journal of Molecular and Cellular Cardiology·K Kobayashi, J R Neely
Dec 1, 1980·Circulation Research·S PenpargkulJ Scheuer
Jun 1, 1994·Journal of the American College of Cardiology·R M BersinK Chatterjee
Oct 1, 1993·Journal of Molecular and Cellular Cardiology·J C Chatham, J R Forder
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert

❮ Previous
Next ❯

Citations

Sep 1, 2001·Environmental Toxicology and Pharmacology·M D ColemanC J Bailey
Dec 17, 2005·Antioxidants & Redox Signaling·Asnat Bloch-Damti, Nava Bashan
Nov 3, 2009·Journal of Diabetes and Its Complications·Mohammed A KandeilEman T Mohammed
Jan 9, 1998·Drug Metabolism Reviews·G BiewengaA Bast
Oct 17, 2009·Drug Development and Industrial Pharmacy·Chul Ho ParkHyoun-Sik Kim
Feb 9, 2000·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·J A PethE J Henriksen
Jun 16, 2001·Journal of Applied Physiology·V SaengsirisuwanE J Henriksen
Dec 18, 2001·Journal of Applied Physiology·Vitoon SaengsirisuwanErik J Henriksen
Apr 28, 2005·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·V ThirunavukkarasuC V Anuradha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.